E1	Condition:T1 Name:T2
E7	Procedure:T7 Name:T8 Temporality:E17
E9	Procedure:T9 Name:T10
E11	Procedure:T11 Name:T12
E13	Procedure:T13 Name:T14 Temporality:E19
E14	Age:T27 Numeric-Filter:E15
E15	Eq-Comparison:T35 Operator:T15 Temporal-Unit:T22 Value:T28
E16	Eq-Comparison:T36 Operator:T16 Value:T29
E17	Eq-Comparison:T37 Operator:T17 Temporal-Unit:T23 Value:T30
E18	Eq-Comparison:T38 Operator:T18 Temporal-Unit:T24 Value:T31
E19	Eq-Comparison:T39 Operator:T19 Temporal-Unit:T25 Value:T32
E20	Eq-Comparison:T40 Operator:T20 Value:T33 Unit:T82 Per:T83
E21	Eq-Comparison:T41 Operator:T21 Value:T34 Unit:T86 Per:T26
E2	Procedure:T5 Name:T6
E3	Negation:T42 Negates:E2
E4	Study:T43 
E8	Observation:T46 Name:T47 Numeric-Filter:E16
E10	Drug:T48 Name:T49
E12	Drug:T50 Name:T51
E22	Drug:T52 Name:T53
E23	Drug:T54 Name:T55
E25	Procedure:T57 Name:T58 Temporality:E26
E26	Eq-Comparison:T60 Temporal-Recency:T59
E28	Drug:T62 Name:T63 Temporality:E18
E35	Procedure:T74 Name:T75
E37	Study:T77 
E39	Study:T79 
E40	Observation:T80 Name:T81 Numeric-Filter:E20
E41	Observation:T84 Name:T85 Numeric-Filter:E21
E43	Condition:T88 Name:T89 Stage:E44
E44	Eq-Comparison:T90 Operator:T93 Unit:T94 Value:T91 Value2:T92
E45	Assertion:T95 Asserted:E3
E47	Assertion:T97 Asserted:E2
E6	Study:T45 
E48	Study:T98 
E51	Study:T101 
E53	Study:T103 
E29	Modifier:T64 Modifies:T63
E30	Modifier:T65 Modifies:T63
E31	Modifier:T66 
E32	Modifier:T67 Modifies:T63
T1	Condition 64 103	Myasthenia Gravis Foundation of America
T2	Condition-Name 64 103	Myasthenia Gravis Foundation of America
T3	Life-Stage-And-Gender 33 39	female
T4	Life-Stage-And-Gender 25 29	Male
T7	Procedure 435 451	immunomodulation
T8	Procedure-Name 435 451	immunomodulation
T9	Procedure 578 593	plasma exchange
T10	Procedure-Name 578 593	plasma exchange
T11	Procedure 563 577	plasmapheresis
T12	Procedure-Name 563 577	plasmapheresis
T13	Procedure 637 647	Thymectomy
T14	Procedure-Name 637 647	Thymectomy
T15	Eq-Operator 40 41	≥
T16	Eq-Operator 239 240	≥
T17	Eq-Operator 452 458	within
T18	Eq-Operator 599 605	within
T19	Eq-Operator 658 659	<
T20	Eq-Operator 711 712	<
T21	Eq-Operator 765 766	<
T22	Eq-Temporal-Unit 45 50	years
T23	Eq-Temporal-Unit 461 467	months
T24	Eq-Temporal-Unit 608 613	weeks
T25	Eq-Temporal-Unit 663 669	months
T26	Eq-Unit 777 780	mm3
T27	Age 54 57	age
T28	Eq-Value 42 44	18
T29	Eq-Value 240 242	12
T30	Eq-Value 459 460	6
T31	Eq-Value 606 607	4
T32	Eq-Value 660 662	12
T33	Eq-Value 712 713	6
T34	Eq-Value 766 770	1500
T35	Eq-Comparison 40 50	≥ 18 years
T36	Eq-Comparison 239 242	≥12
T37	Eq-Comparison 452 467	within 6 months
T38	Eq-Comparison 599 613	within 4 weeks
T39	Eq-Comparison 658 669	< 12 months
T40	Eq-Comparison 711 717	<6 g/L
T41	Eq-Comparison 765 780	<1500 cells/mm3
T5	Procedure 152 162	respirator
T6	Procedure-Name 152 162	respirator
T42	Negation 135 138	not
T43	Study 187 192	study
T46	Observation 229 232	QMG
T47	Observation-Name 229 232	QMG
T48	Drug 371 380	rituximab
T49	Drug-Name 371 380	rituximab
T50	Drug 382 391	belimumab
T51	Drug-Name 382 391	belimumab
T52	Drug 393 403	eculizumab
T53	Drug-Name 393 403	eculizumab
T54	Drug 411 430	monoclonal antibody
T55	Drug-Name 411 430	monoclonal antibody
T57	Procedure 483 489	dosing
T58	Procedure-Name 483 489	dosing
T59	Eq-Temporal-Recency 477 482	first
T60	Eq-Comparison 477 482	first
T62	Drug 496 511	Immunoglobulins
T63	Drug-Name 496 511	Immunoglobulins
T74	Procedure 595 597	PE
T75	Procedure-Name 595 597	PE
T77	Study 621 630	Screening
T79	Study 679 688	screening
T80	Observation 695 704	Total IgG
T81	Observation-Name 695 704	Total IgG
T82	Eq-Unit 714 715	g
T83	Eq-Unit 716 717	L
T84	Observation 739 764	Absolute neutrophil count
T85	Observation-Name 739 764	Absolute neutrophil count
T86	Eq-Unit 771 776	cells
T88	Condition 105 109	MGFA
T89	Condition-Name 105 109	MGFA
T90	Eq-Comparison 111 123	Class II-IVa
T91	Eq-Value 117 119	II
T92	Eq-Value 120 123	IVa
T93	Eq-Operator 119 120	-
T94	Eq-Unit 111 116	Class
T95	Assertion 128 134	likely
T97	Assertion 142 149	need of
T45	Study 246 255	Screening
T98	Study 260 268	Baseline
T101	Study 784 793	screening
T103	Study 722 731	screening
T64	Modifier 521 523	SC
T65	Modifier 525 527	IV
T66	Modifier 529 533	IVIG
T67	Modifier 539 558	intramuscular route
A1	Life-Stage-And-Gender-Type T3 female
A2	Life-Stage-And-Gender-Type T4 male
A3	Eq-Operator-Value T15 GTEQ
A4	Eq-Operator-Value T16 GTEQ
A5	Eq-Operator-Value T17 LTEQ
A6	Eq-Operator-Value T18 LTEQ
A7	Eq-Operator-Value T19 LT
A8	Eq-Operator-Value T20 LT
A9	Eq-Operator-Value T21 LT
A10	Eq-Temporal-Unit-Value T22 year
A11	Eq-Temporal-Unit-Value T23 month
A12	Eq-Temporal-Unit-Value T24 week
A13	Eq-Temporal-Unit-Value T25 month
A16	Observation-Type-Value E8 clinical-score
A17	Eq-Temporal-Recency-Value T59 first-time
A21	Observation-Type-Value E40 clinical-score
A22	Eq-Operator-Value T93 BETWEEN
A23	Assertion-Type-Value E45 hypothetical
A24	Assertion-Type-Value E47 hypothetical
R1	Using Arg1:E7 Arg2:E23
R2	Using Arg1:E7 Arg2:E22
R3	Using Arg1:E7 Arg2:E12
R4	Using Arg1:E7 Arg2:E10
R6	Abbrev-Of Arg1:E35 Arg2:E9
R7	Abbrev-Of Arg1:E43 Arg2:E1
R5	Abbrev-Of Arg1:E31 Arg2:E30
R8	Using Arg1:E28 Arg2:E11
R9	Using Arg1:E28 Arg2:E9
R10	During Arg1:E2 Arg2:E4
R11	Or Arg1:E22 Arg2:E23
R12	Before Arg1:E17 Arg2:E25
R13	Or Arg1:E31 Arg2:E32
R14	Or Arg1:E28 Arg2:E11
R15	Before Arg1:E18 Arg2:E37
R16	Before Arg1:E19 Arg2:E39
R17	Or Arg1:T4 Arg2:T3
R18	And Arg1:E43 Arg2:E45
R19	And Arg1:E6 Arg2:E48
R20	During Arg1:E8 Arg2:E6
R21	During Arg1:E41 Arg2:E51
R22	During Arg1:E40 Arg2:E53
R23	Or Arg1:E10 Arg2:E12
R24	Or Arg1:E12 Arg2:E22
R25	Or Arg1:E29 Arg2:E30
